Results 181 to 190 of about 76,288 (243)

Soluble SARS-CoV-2 Spike glycoprotein: considering some potential pathogenic effects. [PDF]

Front Immunol
Azzarone B, Landolina N, Mariotti FR, Moretta L, Maggi E.   +4 more
europepmc   +1 more source

Genome sequencing of SARS-CoV-2 omicron variants in Delhi reveals alterations in immunogenic regions in spike glycoprotein. [PDF]

Front Immunol, 2023
Shikha S, Jogi MK, Jha R, Kumar RA, Sah T, Singh P, Sagar R, Kumar A, Marwal R, Ponnusamy K, Agarwal SM, Kumar RS, Arif N, Bharadwaj M, Singh S, Kumar P.   +15 more
europepmc   +1 more source

Simulations of pH and thermal effects on SARS-CoV-2 spike glycoprotein. [PDF]

Front Mol Biosci
Niu Z, Kementzidis G, Rafailovich M, Simon M, Papadopoulos E, Aktas BH, Deng Y.   +6 more
europepmc   +1 more source

In Silico Discovery of a Novel Antiviral Scaffold for SARS-CoV‑2 Targeting the Spike Glycoprotein through the Fatty Acid Binding Pocket. [PDF]

ACS Omega
Queirós-Reis L, Kaarbo̷ M, Al-Baldawi H, Alvites R, Maurício AC, Brancale A, Bassetto M, Mesquita JR.   +7 more
europepmc   +1 more source

SARS-CoV-2 Impairs Osteoblast Differentiation Through Spike Glycoprotein and Cytokine Dysregulation. [PDF]

Viruses
Freiberger RN, López CAM, Jarmoluk P, Palma MB, Cevallos C, Sviercz FA, Grosso TM, García MN, Quarleri J, Delpino MV.   +9 more
europepmc   +1 more source

CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy. [PDF]

J Med Virol, 2023
Machado TL, Santos AC, Azamor T, da Silva AMV, Pimenta VR, Tubarão LN, da Silva ADS, Flores Rodrigues DDR, Müller R, Pinto MA, Villar LM, Bom APA, Melgaço JG.   +12 more
europepmc   +1 more source

Identification of an Unnatural Sulfated Monosaccharide as a High-Affinity Ligand for Pan-Variant Targeting of SARS-CoV-2 Spike Glycoprotein. [PDF]

ACS Chem Biol
Thompson A, Sankaranarayanan NV, Chittum JE, Mahida V, Vishweshwara SS, Raigawali R, Anand S, Kikkeri R, Desai UR.   +8 more
europepmc   +1 more source

De novo design of bioactive phenol and chromone derivatives for inhibitors of Spike glycoprotein of SARS-CoV-2 in silico. [PDF]

3 Biotech, 2023
Lima JPO, da Fonseca AM, Marinho GS, da Rocha MN, Marinho EM, Dos Santos HS, Freire RM, Marinho ES, de Lima-Neto P, Fechine PBA.   +9 more
europepmc   +1 more source

Design of nanobody targeting SARS-CoV-2 spike glycoprotein using CDR-grafting assisted by molecular simulation and machine learning. [PDF]

PLoS Comput Biol
Ferraz MVF, Adan WCS, Lima TE, Santos AJC, de Paula SO, Dhalia R, Wallau GL, Wade RC, Viana IFT, Lins RD.   +9 more
europepmc   +1 more source

Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. [PDF]

Immunity, 2023
Liu L, Casner RG, Guo Y, Wang Q, Iketani S, Chan JF, Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L, Ho DD.   +19 more
europepmc   +1 more source